Immunomedics Highlights Publication Of Updated Data From Phase 2 Study Of Sacituzumab Govitecan In Patients With Metastatic Triple-Negative Breast Cancer On NEJM.org; Showed Overall Response rate 33.3%, Median Duration Of Response 7.7 Months
Benzinga Newsdesk